Empliciti is a medication that is used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It is typically prescribed in combination with other medications, such as lenalidomide and dexamethasone, for patients who have received at least one prior therapy.

Empliciti works by targeting a protein called SLAMF7, which is found on the surface of myeloma cells. By binding to this protein, Empliciti helps to activate the body’s immune system to attack and destroy the cancer cells. This mechanism of action makes Empliciti a valuable addition to the treatment regimen for multiple myeloma, as it can help to improve outcomes for patients.

As with any medication, there are potential side effects associated with Empliciti. These can include low blood cell counts, infections, fatigue, and infusion reactions. It is important for patients to discuss these potential side effects with their healthcare provider before starting treatment with Empliciti.

Overall, Empliciti has been shown to be an effective and well-tolerated medication for the treatment of multiple myeloma. It is important for patients to follow their healthcare provider’s instructions carefully and to report any side effects or concerns promptly. By working closely with their healthcare team, patients can maximize the benefits of Empliciti and improve their quality of life.